Uncovering the Success of Dual Brand Strategy for Anti-Obesity Medications: Lessons Learnt from the GLP-1 Boom to Inform Future Strategies
Time: 3:30 pm
day: Conference Day One
Details:
- Defining what constitutes a dual brand strategy in the context of GLP-1 medications, considering separate brands for different indications, different dosages, and different marketing strategies
- Understanding the core motivations behind dual brand strategies for anti-obesity medications
- Analyzing the risks and benefits of dual brand strategy: why has this worked so well for Eli Lilly and Novo Nordisk
- Evaluating the segmentation of patient populations, treatment regimens, clinical profiles, and endpoints for each brand
- Understanding the impact of different dosing strategies on patient outcomes and market perception
